Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Cardiac Fibrosis in the Multi-Omics Era: Implications for Heart Failure
Ghazal, Rachad , Wang, Min , Liu, Duan , Tschumperlin, Daniel J. , Pereira, Naveen L. , Ghazal, Rachad , Wang, Min , Liu, Duan

Mayo Clinic

Circulation Research | March 27, 2025 | Volume: 136 | Issue: 7 | Pages: 773-802

10.1161/circresaha.124.325402 | PMID 40146800 Get It

Cardiac fibrosis, a hallmark of heart failure and various cardiomyopathies, represents a complex pathological process that has long challenged therapeutic intervention. High-throughput omics technologies have begun revolutionizing our understanding of the molecular mechanisms driving cardiac fibrosis and are providing unprecedented insights into its heterogeneity and progression. This review provides a comprehensive analysis of how techniques—encompassing genomics, epigenomics, transcriptomics, proteomics, and metabolomics—are providing insight into our understanding of cardiac fibrosis. Genomic studies have identified novel genetic variants and regulatory networks associated with fibrosis susceptibility and progression, and single-cell transcriptomics has unveiled distinct cardiac fibroblast subpopulations with unique molecular signatures. Epigenomic profiling has revealed dynamic chromatin modifications controlling fibroblast activation states, and proteomic analyses have identified novel biomarkers and potential therapeutic targets. Metabolomic studies have uncovered important alterations in cardiac energetics and substrate utilization during fibrotic remodeling. The integration of these multi-omic data sets has led to the identification of previously unrecognized pathogenic mechanisms and potential therapeutic targets, including cell-type-specific interventions and metabolic modulators. We discuss how these advances are driving the development of precision medicine approaches for cardiac fibrosis while highlighting current challenges and future directions in translating multi-omic insights into effective therapeutic strategies. This review provides a systems-level perspective on cardiac fibrosis that may inform the development of more effective, personalized therapeutic approaches for heart failure and related cardiovascular diseases.
Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
Durbin, Sienna , Zubiri, Leyre , Perlman, Katherine, Wu, Chia‐Yun, Lim, Tristan , Grealish, Kelley, Hathaway, Nora , Jacoby, Ted V. , Shah, Nishi , Mooradian, Meghan J. , Reynolds, Kerry L. , Zubiri, Leyre , LoPiccolo, Jaclyn , Wang, Mike , Falade, Ayo , Molina, Gabriel E.

Mayo Clinic

JAMA Network Open | March 27, 2025 | Volume: 8 | Issue: 3 | Pages: e252668

10.1001/jamanetworkopen.2025.2668 | PMID 40146104 Get It

Importance The use of immune checkpoint inhibitors (ICIs) is increasing. Little is known about the frequency of late-onset immune-related adverse events (irAEs) and the patient-specific risk factors associated with their development. Objectives To assess the incidence of persistent or de novo late-onset irAEs requiring hospitalization and identify patient factors associated with risk of late-onset irAEs. Design, Setting, and Participants This retrospective observational cohort study conducted from January 2011 to October 2022 included patients who received ICIs and were hospitalized with irAEs at an academic medical center. Exclusion criteria included ICI therapy outside of the hospital system and no irAE diagnosis during admission. Data were analyzed from November 15, 2022, to January 8, 2025. Exposure Late-onset irAEs. Main Outcomes and Measures The main study outcomes were (1) incidence of irAE hospitalization at 0 to 6 months (early), more than 6 to 12 months (intermediate), and more than 12 months (late) after ICI initiation and (2) patient factors associated with risk of late-onset irAEs. Results Among the 795 patients hospitalized with irAEs, the median age was 67.3 years (IQR, 58.3-74.8 years); 476 (59.9%) were male. Most patients (n = 517 [65.0%]) received anti–programmed death ligand 1 (PD-L1) and anti–programmed cell death 1 monotherapy, with the most common indications being melanoma (n = 335 [42.1%]) and lung cancer (n = 167 [21.0%]). The median time from start of ICI therapy to hospital admission was 2.7 months (IQR, 1.2-6.1 months), with 14.7% of patients (n = 117 of 795) presenting 6 to 12 months after initial ICI exposure and 10.8% of patients (86 of 795) presenting more than 12 months after initial exposure. The irAEs most likely to present late included those involving the kidney (10 of 32 [31.3%]) and hematologic (5 of 23 [21.7%]) organ systems. In univariate analysis, ICI type was significantly associated with the timing of hospital admission for irAEs; of the 517 patients receiving anti–PD-L1–based therapy, 13.5% (n = 70) presented late compared with 5.4% (9 of 167) receiving dual therapy with anti–cytotoxic T-lymphocyte–associated protein 4 ( P < .001). Patients receiving perioperative ICI therapy were significantly more likely to be admitted at the intermediate interval (16 of 68 [23.5%]) compared with those with metastatic disease (87 of 678 [12.8%]) ( P = .03). Timing of irAE was also significantly associated with active ICI exposure; among the patients presenting late, 7.4% (48 of 651) had received ICI therapy within the last 60 days compared with 26.4% (38 of 144) who had not had recent ICI exposure ( P < .001). Conclusions and Relevance The findings of this retrospective observational cohort study suggest that late irAEs are possible, with a subset of patients presenting years after the start of ICI therapy. Clinicians must remain vigilant for irAEs regardless of elapsed time from ICI therapy, especially as patients live longer and ICIs become more widely used. Future investigations are needed to better understand the risk factors for late-onset irAEs and the distinct immunologic pathways that underlie such events.
Targeting senescence in Amyotrophic Lateral Sclerosis: senolytic treatment improves neuromuscular function and preserves cortical excitability in a TDP-43Q331K mouse model.
Viteri*, Jose A., Kerr*, Nathan R., Brennan*, Charles D., Kick, Grace Robinson , Wang, Meifang , Snyder, Harper K., Moore, Peter J., Darvishi, Fereshteh B. , Dashtmian, Anna R. , Ayyagari, Sindhuja N. , Rich, Kelly , Arnold, W. David, Zhu, Yi , Viteri*, Jose A., Kerr*, Nathan R., Brennan*, Charles D., Ketabforoush, Arsh Haj Mohamad Ebrahim , Snyder, Harper K., Moore, Peter J., Zhu, Yi , Arnold, W. David

Mayo Clinic

No container title available | March 27, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6081213/v1 | PMID 40196013 Get It

Abstract Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder marked by progressive motor neuron degeneration in the primary motor cortex (PMC) and spinal cord. Aging is a key factor in ALS onset and progression, with evidence suggesting that biological aging—a process involving cellular decline— far outpaces chronological aging in ALS. This promotes senescent cell accumulation—marked by irreversible cell-cycle arrest, impaired apoptosis, and chronic inflammation—disrupting tissue homeostasis and impairing neuronal support functions. Thus, targeting senescence presents a novel therapeutic strategy for ALS. Here, we investigated the senolytic combination Dasatinib and Quercetin (D&Q) in TDP-43 Q331K ALS mice. D&Q improved neuromuscular function and reduced plasma neurofilament light chain, a biomarker of axonal damage. The most pronounced improvement was the improved cortical excitability, accompanied by reductions in senescence and TDP-43 in the PMC. These findings highlight the potential of senolytics to mitigate ALS-related dysfunction, supporting their viability as a therapeutic strategy. *Jose A. Viteriab, Nathan R. Kerrab, and Charles D. Brennana are co-first authors.
Outcomes Following Radiation Therapy for Embryonal Tumor with Multilayered Rosettes (ETMR): Results from the Pediatric Proton/Photon Consortium Registry (PPCR)
Krisch, Jacquelyn M., Perkins, Stephanie M., Chang, John, MacEwan, Iain, Yock, Torunn I. , Aridgides, Paul , Ermoian, Ralph P. , Indelicato, Daniel J. , Lee, Jae Young , Perentesis, John P. , Laack, Nadia N. , Wolden, Suzanne L. , Wang, Dongliang

Mayo Clinic

No container title available | March 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6273163/v1 Get It

Abstract Purpose: Embryonal tumor with multilayered rosettes (ETMR) is a rare pediatric CNS embryonal tumor with poor survival. The Pediatric Proton/Photon Consortium Registry (PPCR) was queried for outcomes data from prospectively consenting pediatric patients with ETMR treated with proton radiation therapy (RT). Methods: 20 patients (2013-2021) at 9 institutions had ETMR; 2 with prior RT were excluded from statistical analyses (PPCR ETMR, N=18). Overall Survival (OS) and Event Free Survival (EFS) analyses were performed using the Kaplan-Meier method and log-rank values. Median follow-up was calculated using the reverse Kaplan-Meier method. Results: Median age at RT was 3.0 years (1.7-12.2); median follow-up was 55.5 months (2.6-119.4). 8 patients (44%) expired and 6 patients (33%) are surviving ≥55 months. 11 (61%) patients received systemic therapy with stem cell support. The majority (89%) had focal RT, while 2 patients received craniospinal irradiation (CSI). 4-year OS and EFS were 59.6% and 54.2%, respectively. Local control (LC) at 4 years was 81%. No differences in OS or EFS were observed for receipt of systemic therapy with stem cell support (p=0.361, p=0.57), progression prior to RT (p=0.127, p=0.18), or surgery to RT ≥200 days (p=0.35, p=0.254). Symptomatic radionecrosis was not reported. Conclusion: Focal proton RT provided effective local control as part of multimodality therapy for ETMR, with encouraging survival for this rare and often infant age tumor. Outcomes for CSI were limited to 2 patients treated upfront, and 1 patient receiving salvage CSI for disseminated relapse after focal RT who is surviving >1 year. Trial: DFCI protocol 12-103, clinicaltrials.gov NCT01696721, date of registration 9/27/2012
355 Validation of an artificial intelligence Algorithm for predicting diagnosis-related groups in a community health system
Muhanga, Angela, King, Jason, Mueller, Jennifer L., Sanger, Julie M., Bartlett, Brian N., Manz, Brian N., Spiten, James W., Overgaard, Shauna M., Wang, Hanyin, King, Jason, Mueller, Jennifer L., Sanger, Julie M., Bartlett, Brian N., Spiten, Matthew J., Overgaard, Shauna M., Wang, Hanyin

Mayo Clinic

Journal of Clinical and Translational Science | March 25, 2025 | Volume: 9 | Issue: s1 | Pages: 109-109

10.1017/cts.2024.981 Get It

Objectives/Goals: This study aims to evaluate the performance of a third-party artificial intelligence (AI) product in predicting diagnosis-related groups (DRGs) in a community healthcare system. We highlight a use case illustrating how clinical practice leverages AI-predicted information in unexpected yet advantageous ways and assess the AI predictions accuracy and practical application. Methods/Study Population: DRGs are crucial for hospital reimbursement under the prospective payment model. The Mayo Clinic Health System (MCHS), a network of clinics and hospitals serving a substantial rural population in Minnesota and Wisconsin, has recently adopted an AI algorithm developed by Xsolis (an AI-focused healthcare solution provider). This algorithm, a 1D convolutional neural network, predicts DRGs based on clinical documentation. To assess the accuracy of AI-generated DRG predictions for inpatient discharges, we analyzed data from 930 patients hospitalized at MCHS Mankato between March 2 and May 13, 2024. The Xsolis platform provided the top three DRG predictions for the first 48 hours of each inpatient stay. The accuracy of these predictions was then compared against the final billed DRG codes from the hospital’s records. Results/Anticipated Results: In our validation set, Xsolis achieved a top-3 DRG prediction accuracy of 71% at 24 hours and 81% at 48 hours, which is lower than the originally reported accuracy of 81.1% and 83.3%, respectively. Interestingly, discussions with clinical practice leaders revealed that the most valuable information derived from the AI predictions was the expected geometric mean length of stay (GMLOS), which Xsolis was perceived to predict accurately. In the Medicare system, each DRG is associated with an expected GMLOS, a critical factor for efficient hospital flow planning. A subsequent analysis comparing predicted GMLOS with the actual length of stay showed variances of -0.10 days on day 1 and 0.14 days on day 2, indicating a high degree of accuracy and aligning with clinical practice perceptions. Discussion/Significance of Impact: Our research underscores that clinical practice can leverage AI predictions in unexpected yet beneficial ways. While initially focused on DRG prediction, the associated GMLOS emerged as more significant. This suggests that AI algorithm validation should be tailored to specific clinical needs rather than relying solely on generalized benchmarks.
Hypertension and Atrial Fibrillation: A Frontier Review From the AF-SCREEN International Collaboration
Schnabel, Renate B. , Schutte, Aletta E. , Buckley, Claire , Cameron, Alan C. , Damasceno, Albertino , Diederichsen, Søren Zöga , Doehner, Wolfram , Joung, Boyoung , Hankey, Graeme J. , Lobban, Trudie , Mairesse, Georges H. , Svendsen, Jesper Hastrup , Tieleman, Robert G , Wang, Ji‐Guang , Niiranen, Teemu J , Schnabel, Renate B , Schutte, Aletta E , Boriani, Giuseppe , Buckley, Claire , Cameron, Alan C , Damasceno, Albertino , Diederichsen, Søren Z , Doehner, Wolfram , Guo, Yutao , Hobbs, F D Richard , Joung, Boyoung , Hankey, Graeme J , Lip, Gregory Y H , Lobban, Trudie , Løchen, Maja-Lisa , Mairesse, Georges , Mbakwem, Amam , Noseworthy, Peter A , Steinhubl, Steven , Stergiou, George , Svendsen, Jesper Hastrup , Tieleman, Robert G , Wang, Ji-Guang , Poulter, Neil R , Healey, Jeffrey S , Freedman, Ben , Biton, Yitschak , Boriani, Giuseppe , Hobbs, Richard , Mbakwem, Amam , Noseworthy, Peter A. , Ntaios, George , Stergiou, George S. , Healey, Jeff S. , Freedman, Ben

Mayo Clinic

Circulation | March 24, 2025 | Volume: 151 | Issue: 12 | Pages: 863-877

10.1161/circulationaha.124.071047 | PMID 40127157 Get It

Hypertension is the leading modifiable risk factor for atrial fibrillation (AF) and is estimated to be present in >70% of AF patients. This Frontiers Review was prepared by 29 expert members of the AF-SCREEN International Collaboration to summarize existing evidence and knowledge gaps on links between hypertension, AF, and their cardiovascular sequelae; simultaneous screening for hypertension and AF; and the prevention of AF through antihypertensive therapy. Hypertension and AF are inextricably connected. Both are easily diagnosed, often silent, and frequently treated inadequately. Together, they additively increase the risk of ischemic stroke, heart failure, and many types of dementia, resulting in greater all-cause mortality, considerable disease burden, and increased health care expenditures. Automated upper arm cuff blood pressure devices with implemented technology can be used to simultaneously detect both hypertension and AF. However, positive screening for AF with an oscillometric blood pressure monitor still requires ECG confirmation. The current evidence suggests that high-risk individuals aged ≥65 years or with treatment-resistant hypertension could benefit from AF screening. Since antihypertensive therapy effectively lowers AF risk, particularly in individuals with left ventricular dysfunction, hypertension should be the key target for AF prediction and prevention rather than merely a comorbidity of AF. Nevertheless, several important gaps in knowledge need to be filled over the next years, including the ideal method and selection of patients for simultaneous screening of hypertension and AF and the optimal antihypertensive drug class and blood pressure targets for AF prevention.
The Cleveland Clinic Post-ICU Recovery Clinic: Early Experience During the COVID-19 Pandemic
Kommaraju, Kavya, Torbic, Heather , Veith, Joshua, Wang, Xiaofeng , Biehl, Michelle

Mayo Clinic

Journal of Intensive Care Medicine | March 24, 2025 | Volume: 40 | Issue: 8 | Pages: 893-901

10.1177/08850666251326551 | PMID 40123228 Get It

Background Over half of ICU survivors experience post intensive care syndrome (PICS). Few PICS clinics were operational in the United States at the onset of the COVID-19 pandemic. Here we describe early experience of such a clinic at a large academic medical center. Our objective was to describe the (a) model of care (b) clinic interventions (c) short-term cognitive, psychiatric, and functional outcomes (d) one-year outcomes of COVID-19 ICU survivors at the Cleveland Clinic post-ICU recovery clinic (PIRC). Methods We conducted a retrospective cohort study through a chart review of all patients seen in PIRC from April 2020 – December 2020. A total of 59 patients completed the visit with 49% being virtual, and 51% being in-person. The cohort was predominantly white (50.8%), and male (57.6%) with a median age of 58.2 years. We screened for cognitive and psychiatric impairments using several different validated questionnaires. Functional impairments were self-reported and detected after assessment by a physical therapist. Quantifiable clinic interventions were referrals, pharmacy medication reconciliation, and vaccine administration. One-year outcomes were health care utilization, and death. Results In our cohort, 36%, 39.6%, and 17% of patients screened positive for cognitive impairment, anxiety and/or depression, and PTSD respectively. 42.3% of patients had lower extremity mobility impairment. 57.6% of patients required at least one referral after clinic. Of the 67.9% of patients who were working and 93.9% driving prior to hospitalization, only 24.6% and 73.2% had returned to those activities, respectively. The most common pharmacy intervention was discontinuation of a medication no longer in use. By one year, 34% of patients had hospital re-admissions with 5% requiring the ICU. There were no deaths. Conclusions Adult survivors of COVID-19 critical illness have impairments in all PICS domains as well as high health care utilization in the first year after hospital discharge. MeSH Terms Post intensive care syndrome, COVID-19 Key Points/Summary Adult survivors of COVID-19 critical illness have impairments in all PICS domains as well as high health care utilization in the first year after hospital discharge. Post-ICU recovery clinics can help survivors with recovery.
Impact of the day of the week on clinical outcomes following anterior cervical discectomy and fusion surgery
Woo, Joshua , Johnson, Sarah E. , Barrett, Connor , Bydon, Mohamad , Bisson, Erica F. , Haid, Regis W., Glassman, Steven D. , Chan, Andrew K. , Chou, Dean , Wang, Michael Y. , Knightly, John J. , Gottfried, Oren N., Shaffrey, Christopher I., Virk, Michael S., Fu, Kai-Ming, Shaffrey, Mark E., Foley, Kevin T. , Upadhyaya, Cheerag D., Potts, Eric A. , Tumialán, Luis M. , Turner, Jay D. , Uribe, Juan S. , McGirt, Matthew J., Kim, Paul K., Mummaneni, Praveen V. , Than, Khoi D. , Bergin, Stephen M., Michalopoulos, Giorgos D. , Shaffrey, Christopher I. , Virk, Michael S., Fu, Kai-Ming, Park, Paul , Kim, Paul K.

Mayo Clinic

Journal of Neurosurgery: Spine | March 22, 2025 | Volume: 42 | Issue: 6 | Pages: 737-747

10.3171/2024.11.spine24609 | PMID 40117661 Get It

OBJECTIVE Previous research suggests elective surgical procedures performed later in the week have worse outcomes. This study investigated whether the day of the week on which elective anterior cervical discectomy and fusion (ACDF) surgery was performed impacts clinical outcomes. METHODS Using data from the Quality Outcomes Database, a nationwide, multicenter prospective registry, this study included patients undergoing elective ACDF for cervical spondylosis. Patients were categorized into groups based on the surgery day (early week, Monday and Tuesday; late week, Thursday and Friday). Analyzed outcomes included postoperative complications, readmissions, reoperations, and patient-reported outcomes. Statistical methods included the independent t-test, Pearson’s chi-square test, and multivariable logistic regression. RESULTS The study analyzed 19,818 patients, with 41.7% undergoing surgery early in the week and 36.9% later. There were no significant differences in 30-day mortality, readmissions, or reoperations between the two groups. Early-week surgical procedures were associated with a higher incidence of postoperative dysphagia requiring nasogastric tubes (0.6% vs 0.3%, p = 0.02) and a higher incidence of vocal cord paralysis (0.5% vs 0.3%, p = 0.01). The data indicate a surgical selection bias with more complex surgical procedures and higher risk patients typically scheduled earlier in the week, which likely contributed to the increased rates of dysphagia. Conversely, patients who underwent operations on Fridays were more likely to be discharged on the same day compared to those earlier in the week (p = 0.02), without a significant difference in length of stay overall. Surgical procedures performed later in the week were more likely to be performed at ambulatory surgical centers rather than inpatient facilities (p < 0.01), indicating a strategic selection of healthier patients for end-of-week procedures. CONCLUSIONS The day of elective ACDF surgery does not affect mortality, readmissions, or reoperation rates. However, early-week surgical procedures may see slightly higher rates of postoperative dysphagia and vocal cord paralysis, likely due to the scheduling of more complex cases or higher risk patients during these days. Overall, the authors’ data confirm that day of surgery does not influence overall patient recovery significantly. This information is useful for surgical planning and for providing patient reassurance that the day of the week does not significantly impact surgical outcomes.